2026 Q2 -tulosraportti
UUTTA
6 päivää sitten
‧51 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 300 | - | - | ||
| 1 200 | - | - | ||
| 1 600 | - | - | ||
| 4 000 | - | - | ||
| 3 510 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 1.9. | ||
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·49 min sittenalgo is accumulating buys all the way.. only a short time until it shoots up.
·52 min sittenPeople should go to circio's website and read the info there. There's a lot and it's very well explained about their upcoming ventures etc. Buy and hold
·52 min sittenCircio against the rest: How unique is circVec – and how big can the value become? Folks, I've taken a closer look at who actually competes with Circio, and I find this quite interesting. There are several companies working with circular RNA and in vivo CAR-T, but I can't find any that seem to be working with exactly the same solution as Circio. That's an important difference. Companies like Orna, Orbital, RiboX, and Therorna primarily work with synthetic circRNA that is produced outside the body and then delivered into the cells, often via LNP. Circio does something different. Circio delivers the DNA recipe, allowing the cell itself to produce circRNA inside the body. In my opinion, that is the key to circVec. Some of the competitors are actually further ahead clinically than Circio. RiboX and Therorna have come closer to or entered clinical trials in in vivo CAR-T. We shouldn't pretend otherwise. But the question isn't just who is furthest ahead. The question is also: Who holds the technology that could become the best if it works as the data now suggests? And that's where I think Circio is starting to become very interesting. Within AAV gene therapy, Circio isn't necessarily trying to replace existing technology either. They are trying to make existing AAV significantly better. This means that companies that today might be perceived as competitors, tomorrow could just as easily become customers, licensing partners, or collaborators. I think that's an extremely important point. We have already seen up to 60x higher expression in several tissues, therapeutic gene in vivo, and Gen 5 components pointing towards a potentially 200x+ improvement. If this eventually also yields better effect in disease models, then we're starting to talk about something completely different than just promising laboratory data. And then we must remember what Big Pharma has already done in this field. BMS bought Orbital. Lilly bought Orna. Both were bought because large pharmaceutical companies see strategic value in circular RNA and in vivo cell therapy. And the interesting thing is that these companies didn't necessarily have technology identical to circVec. So for me, the competitive landscape is actually quite simple: Within synthetic circRNA, there are several strong competitors. Within in vivo CAR-T, there is fierce competition. But within DNA-/vector-based production of circRNA inside the cell, I find no clearly established competitor doing exactly the same as Circio. This is what makes the whole case so exciting. If Circio now goes from: 60x expression → therapeutic gene → disease model → therapeutic effect → Gen 5 → partnership then it could quickly become wrong to compare Circio with small preclinical biotech companies. Then the comparison might rather become: What was Orbital worth before BMS bought them? What was Orna worth before Lilly bought them? And that's a completely different discussion. I'm not saying acquisitions will happen tomorrow. But the more data that confirms circVec, the more interesting the question becomes: How long will Circio actually get to develop this technology alone before a larger player decides they want to own it?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 -tulosraportti
UUTTA
6 päivää sitten
‧51 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·49 min sittenalgo is accumulating buys all the way.. only a short time until it shoots up.
- ·52 min sittenPeople should go to circio's website and read the info there. There's a lot and it's very well explained about their upcoming ventures etc. Buy and hold
- ·52 min sittenCircio against the rest: How unique is circVec – and how big can the value become? Folks, I've taken a closer look at who actually competes with Circio, and I find this quite interesting. There are several companies working with circular RNA and in vivo CAR-T, but I can't find any that seem to be working with exactly the same solution as Circio. That's an important difference. Companies like Orna, Orbital, RiboX, and Therorna primarily work with synthetic circRNA that is produced outside the body and then delivered into the cells, often via LNP. Circio does something different. Circio delivers the DNA recipe, allowing the cell itself to produce circRNA inside the body. In my opinion, that is the key to circVec. Some of the competitors are actually further ahead clinically than Circio. RiboX and Therorna have come closer to or entered clinical trials in in vivo CAR-T. We shouldn't pretend otherwise. But the question isn't just who is furthest ahead. The question is also: Who holds the technology that could become the best if it works as the data now suggests? And that's where I think Circio is starting to become very interesting. Within AAV gene therapy, Circio isn't necessarily trying to replace existing technology either. They are trying to make existing AAV significantly better. This means that companies that today might be perceived as competitors, tomorrow could just as easily become customers, licensing partners, or collaborators. I think that's an extremely important point. We have already seen up to 60x higher expression in several tissues, therapeutic gene in vivo, and Gen 5 components pointing towards a potentially 200x+ improvement. If this eventually also yields better effect in disease models, then we're starting to talk about something completely different than just promising laboratory data. And then we must remember what Big Pharma has already done in this field. BMS bought Orbital. Lilly bought Orna. Both were bought because large pharmaceutical companies see strategic value in circular RNA and in vivo cell therapy. And the interesting thing is that these companies didn't necessarily have technology identical to circVec. So for me, the competitive landscape is actually quite simple: Within synthetic circRNA, there are several strong competitors. Within in vivo CAR-T, there is fierce competition. But within DNA-/vector-based production of circRNA inside the cell, I find no clearly established competitor doing exactly the same as Circio. This is what makes the whole case so exciting. If Circio now goes from: 60x expression → therapeutic gene → disease model → therapeutic effect → Gen 5 → partnership then it could quickly become wrong to compare Circio with small preclinical biotech companies. Then the comparison might rather become: What was Orbital worth before BMS bought them? What was Orna worth before Lilly bought them? And that's a completely different discussion. I'm not saying acquisitions will happen tomorrow. But the more data that confirms circVec, the more interesting the question becomes: How long will Circio actually get to develop this technology alone before a larger player decides they want to own it?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 300 | - | - | ||
| 1 200 | - | - | ||
| 1 600 | - | - | ||
| 4 000 | - | - | ||
| 3 510 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 1.9. | ||
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 |
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 -tulosraportti
UUTTA
6 päivää sitten
‧51 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 1.9. | ||
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·49 min sittenalgo is accumulating buys all the way.. only a short time until it shoots up.
- ·52 min sittenPeople should go to circio's website and read the info there. There's a lot and it's very well explained about their upcoming ventures etc. Buy and hold
- ·52 min sittenCircio against the rest: How unique is circVec – and how big can the value become? Folks, I've taken a closer look at who actually competes with Circio, and I find this quite interesting. There are several companies working with circular RNA and in vivo CAR-T, but I can't find any that seem to be working with exactly the same solution as Circio. That's an important difference. Companies like Orna, Orbital, RiboX, and Therorna primarily work with synthetic circRNA that is produced outside the body and then delivered into the cells, often via LNP. Circio does something different. Circio delivers the DNA recipe, allowing the cell itself to produce circRNA inside the body. In my opinion, that is the key to circVec. Some of the competitors are actually further ahead clinically than Circio. RiboX and Therorna have come closer to or entered clinical trials in in vivo CAR-T. We shouldn't pretend otherwise. But the question isn't just who is furthest ahead. The question is also: Who holds the technology that could become the best if it works as the data now suggests? And that's where I think Circio is starting to become very interesting. Within AAV gene therapy, Circio isn't necessarily trying to replace existing technology either. They are trying to make existing AAV significantly better. This means that companies that today might be perceived as competitors, tomorrow could just as easily become customers, licensing partners, or collaborators. I think that's an extremely important point. We have already seen up to 60x higher expression in several tissues, therapeutic gene in vivo, and Gen 5 components pointing towards a potentially 200x+ improvement. If this eventually also yields better effect in disease models, then we're starting to talk about something completely different than just promising laboratory data. And then we must remember what Big Pharma has already done in this field. BMS bought Orbital. Lilly bought Orna. Both were bought because large pharmaceutical companies see strategic value in circular RNA and in vivo cell therapy. And the interesting thing is that these companies didn't necessarily have technology identical to circVec. So for me, the competitive landscape is actually quite simple: Within synthetic circRNA, there are several strong competitors. Within in vivo CAR-T, there is fierce competition. But within DNA-/vector-based production of circRNA inside the cell, I find no clearly established competitor doing exactly the same as Circio. This is what makes the whole case so exciting. If Circio now goes from: 60x expression → therapeutic gene → disease model → therapeutic effect → Gen 5 → partnership then it could quickly become wrong to compare Circio with small preclinical biotech companies. Then the comparison might rather become: What was Orbital worth before BMS bought them? What was Orna worth before Lilly bought them? And that's a completely different discussion. I'm not saying acquisitions will happen tomorrow. But the more data that confirms circVec, the more interesting the question becomes: How long will Circio actually get to develop this technology alone before a larger player decides they want to own it?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 300 | - | - | ||
| 1 200 | - | - | ||
| 1 600 | - | - | ||
| 4 000 | - | - | ||
| 3 510 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt